Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients

Seoul National University Hospital217 enrolled

Overview

To test the effect of low-dose dexmedetomidine for lowering the incidence of postoperative delirium in liver transplant patients in the ICU. Single center prospective randomized placebo controlled clinical trial 0.1mcg/kg/hr of dexmedetomidine or equivalent amount of saline infusion started after induction of anesthesia for liver transplantation and continued until 48 hours after surgery. Outcomes will be assessed up to 1 week or transfer to ward, whichever comes first.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

217

Conditions

Liver Transplantation

Interventions

PrecedexDRUG

infusion of 0.1mcg/kg/hr of precedex

placebo controlDRUG

placebo

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients (18years old or older) undergoing living-donor or deceased-donor liver transplantation Exclusion Criteria: * Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine

Locations (1)

Seoul National University Hospital

Seoul, Agree, South Korea

Outcomes

Primary Outcomes

analysis of the incidence of postoperative delirium in liver transplant patients in the ICU.

after August 25, 2014

Time frame: 1 week or transfer to ward, whichever comes first.

Secondary Outcomes

analysis of the duration of postoperative delirium, ICU length of stay in liver transplant patients in the ICU.

after August 26, 2014

Time frame: 1 week or transfer to ward, whichever comes first.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.